Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial-Reference-Cited by-同舟云学术

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

Published:2020 Issue:5 Volume:5 Page:e000911
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Sartore-Bianchi Andrea^ORCID,Lonardi Sara,Martino Cosimo^ORCID,Fenocchio Elisabetta,Tosi Federica,Ghezzi Silvia,Leone Francesco,Bergamo Francesca,Zagonel Vittorina,Ciardiello Fortunato,Ardizzoni Andrea,Amatu Alessio^ORCID,Bencardino Katia,Valtorta Emanuele,Grassi Elena,Torri Valter,Bonoldi Emanuela,Sapino Anna,Vanzulli Angelo,Regge Daniele,Cappello Giovanni,Bardelli Alberto,Trusolino Livio,Marsoni Silvia^ORCID,Siena Salvatore^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

3. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation;npj Precision Oncology;2024-09-09

4. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

5. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial;The Lancet Oncology;2024-09